spermidine has been researched along with Obesity in 15 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
Excerpt | Relevance | Reference |
---|---|---|
"Spermidine-mediated protective impacts involve the regulation of lipid metabolism, inflammation response, gut barrier function and thermogenesis." | 8.02 | Spermidine ameliorates high-fat diet-induced hepatic steatosis and adipose tissue inflammation in preexisting obese mice. ( Fu, Z; Hu, L; Ma, L; Ni, L; Ni, Y; Yang, S; Zhao, Y; Zheng, L, 2021) |
"Spermidine serves as an oral supplement to attenuate obesity and metabolic disorders through hypothalamus-dependent or -independent BAT activation and skeletal muscle adaptation." | 8.02 | Oral Spermidine Targets Brown Fat and Skeletal Muscle to Mitigate Diet-Induced Obesity and Metabolic Disorders. ( Guo, C; Jia, Y; Jie, H; Li, R; Li, Y; Mao, H; Tao, Y; Wang, D; Wang, Q; Yin, J; Zhang, L; Zhao, J; Zhou, Z; Zhu, F, 2021) |
"In this study, treatment of high-fat diet-induced obesity (DIO) C57BL/6J mice with spermidine decreased body weight and subcutaneous and visceral fat content, reversed the apparent hepatosteatosis, and reduced hepatic intracellular and serum triglyceride and total cholesterol concentrations." | 7.88 | Spermidine ameliorates non-alcoholic fatty liver disease through regulating lipid metabolism via AMPK. ( Bi, Y; Du, Y; Fang, F; Gao, M; Li, C; Li, M; Liu, X; Xie, X; Zhao, W, 2018) |
"HFD induced cardiac hypertrophy as demonstrated by higher volumes of the left ventricle, cardiomyocytes, interstitium, myofibrils and cardiomyocyte mitochondria." | 5.62 | Voluntary activity reverses spermidine-induced myocardial fibrosis and lipid accumulation in the obese male mouse. ( Bornemann, M; Mühlfeld, C; Pfeiffer, C; Schipke, J; Schneider, V, 2021) |
"Obesity is associated with lung function impairment and respiratory diseases; however, the underlying pathophysiological mechanisms are still elusive, and therapeutic options are limited." | 5.56 | Spermidine supplementation and voluntary activity differentially affect obesity-related structural changes in the mouse lung. ( Ahrendt, N; Eisenberg, T; Lopez-Rodriguez, E; Madeo, F; Magnes, C; Mühlfeld, C; Ochs, M; Rajces, A; Schipke, J; Schmiedl, A; Sedej, S; Steingrüber, T, 2020) |
"Background: Spermidine, a natural polyamine, appears to be a promising intervention for the treatment of obesity in animal studies, but epidemiological studies on the association between spermidine and obesity are inadequate." | 4.12 | Elevation of Serum Spermidine in Obese Patients: Results from a Cross-Sectional and Follow-Up Study. ( Feng, W; Gao, H; Gu, C; Guo, H; Li, R; Ma, Y; Sun, Z; Xu, J; Yuan, W; Zhang, Q; Zheng, L, 2022) |
"Spermidine-mediated protective impacts involve the regulation of lipid metabolism, inflammation response, gut barrier function and thermogenesis." | 4.02 | Spermidine ameliorates high-fat diet-induced hepatic steatosis and adipose tissue inflammation in preexisting obese mice. ( Fu, Z; Hu, L; Ma, L; Ni, L; Ni, Y; Yang, S; Zhao, Y; Zheng, L, 2021) |
"Spermidine serves as an oral supplement to attenuate obesity and metabolic disorders through hypothalamus-dependent or -independent BAT activation and skeletal muscle adaptation." | 4.02 | Oral Spermidine Targets Brown Fat and Skeletal Muscle to Mitigate Diet-Induced Obesity and Metabolic Disorders. ( Guo, C; Jia, Y; Jie, H; Li, R; Li, Y; Mao, H; Tao, Y; Wang, D; Wang, Q; Yin, J; Zhang, L; Zhao, J; Zhou, Z; Zhu, F, 2021) |
"In this study, treatment of high-fat diet-induced obesity (DIO) C57BL/6J mice with spermidine decreased body weight and subcutaneous and visceral fat content, reversed the apparent hepatosteatosis, and reduced hepatic intracellular and serum triglyceride and total cholesterol concentrations." | 3.88 | Spermidine ameliorates non-alcoholic fatty liver disease through regulating lipid metabolism via AMPK. ( Bi, Y; Du, Y; Fang, F; Gao, M; Li, C; Li, M; Liu, X; Xie, X; Zhao, W, 2018) |
"HFD induced cardiac hypertrophy as demonstrated by higher volumes of the left ventricle, cardiomyocytes, interstitium, myofibrils and cardiomyocyte mitochondria." | 1.62 | Voluntary activity reverses spermidine-induced myocardial fibrosis and lipid accumulation in the obese male mouse. ( Bornemann, M; Mühlfeld, C; Pfeiffer, C; Schipke, J; Schneider, V, 2021) |
"Obesity is associated with lung function impairment and respiratory diseases; however, the underlying pathophysiological mechanisms are still elusive, and therapeutic options are limited." | 1.56 | Spermidine supplementation and voluntary activity differentially affect obesity-related structural changes in the mouse lung. ( Ahrendt, N; Eisenberg, T; Lopez-Rodriguez, E; Madeo, F; Magnes, C; Mühlfeld, C; Ochs, M; Rajces, A; Schipke, J; Schmiedl, A; Sedej, S; Steingrüber, T, 2020) |
"Obesity is associated with impaired intestinal barrier function and dysbiosis of the gut microbiota." | 1.56 | Spermidine improves gut barrier integrity and gut microbiota function in diet-induced obese mice. ( Fu, Z; Hu, L; Ma, L; Ni, L; Ni, Y; Tu, W; Wang, Z; Zhao, Y; Zheng, A; Zheng, L; Zhuge, F, 2020) |
"Obesity is associated with risks for mother and infant, and the mothers' dietary habits influence breast milk composition." | 1.39 | Lower polyamine levels in breast milk of obese mothers compared to mothers with normal body weight. ( Ali, MA; Palme-Kilander, C; Strandvik, B; Yngve, A, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (6.67) | 18.2507 |
2000's | 1 (6.67) | 29.6817 |
2010's | 5 (33.33) | 24.3611 |
2020's | 8 (53.33) | 2.80 |
Authors | Studies |
---|---|
Gao, H | 1 |
Zhang, Q | 1 |
Xu, J | 1 |
Yuan, W | 1 |
Li, R | 2 |
Guo, H | 1 |
Gu, C | 1 |
Feng, W | 1 |
Ma, Y | 1 |
Sun, Z | 1 |
Zheng, L | 3 |
Nakatani, S | 1 |
Horimoto, Y | 1 |
Nakabayashi, N | 1 |
Karasawa, M | 1 |
Wada, M | 1 |
Kobata, K | 1 |
Samarra, I | 1 |
Ramos-Molina, B | 1 |
Queipo-Ortuño, MI | 1 |
Tinahones, FJ | 1 |
Arola, L | 1 |
Delpino-Rius, A | 1 |
Herrero, P | 1 |
Canela, N | 1 |
Ahrendt, N | 1 |
Steingrüber, T | 1 |
Rajces, A | 1 |
Lopez-Rodriguez, E | 1 |
Eisenberg, T | 1 |
Magnes, C | 1 |
Madeo, F | 1 |
Sedej, S | 1 |
Schmiedl, A | 1 |
Ochs, M | 1 |
Mühlfeld, C | 2 |
Schipke, J | 2 |
Pfeiffer, C | 1 |
Schneider, V | 1 |
Bornemann, M | 1 |
Ma, L | 2 |
Ni, Y | 2 |
Wang, Z | 1 |
Tu, W | 1 |
Ni, L | 2 |
Zhuge, F | 1 |
Zheng, A | 1 |
Hu, L | 2 |
Zhao, Y | 2 |
Fu, Z | 2 |
Yang, S | 1 |
Liao, CY | 1 |
Kummert, OMP | 1 |
Bair, AM | 1 |
Alavi, N | 1 |
Alavi, J | 1 |
Miller, DM | 1 |
Bagga, I | 1 |
Schempf, AM | 1 |
Hsu, YM | 1 |
Woods, BD | 1 |
Brown Mayfield, SM | 1 |
Mitchell, AN | 1 |
Tannady, G | 1 |
Talbot, AR | 1 |
Dueck, AM | 1 |
Barrera Ovando, R | 1 |
Parker, HD | 1 |
Wang, J | 1 |
Schoeneweis, JK | 1 |
Kennedy, BK | 1 |
Wang, D | 1 |
Yin, J | 1 |
Zhou, Z | 1 |
Tao, Y | 1 |
Jia, Y | 1 |
Jie, H | 1 |
Zhao, J | 1 |
Li, Y | 1 |
Guo, C | 1 |
Zhu, F | 1 |
Mao, H | 1 |
Zhang, L | 1 |
Wang, Q | 1 |
Gao, M | 1 |
Zhao, W | 1 |
Li, C | 1 |
Xie, X | 1 |
Li, M | 1 |
Bi, Y | 1 |
Fang, F | 1 |
Du, Y | 1 |
Liu, X | 1 |
Ali, MA | 1 |
Strandvik, B | 1 |
Palme-Kilander, C | 1 |
Yngve, A | 1 |
Bonhoure, N | 1 |
Byrnes, A | 1 |
Moir, RD | 1 |
Hodroj, W | 1 |
Preitner, F | 1 |
Praz, V | 1 |
Marcelin, G | 1 |
Chua, SC | 1 |
Martinez-Lopez, N | 1 |
Singh, R | 1 |
Moullan, N | 1 |
Auwerx, J | 1 |
Willemin, G | 1 |
Shah, H | 1 |
Hartil, K | 1 |
Vaitheesvaran, B | 1 |
Kurland, I | 1 |
Hernandez, N | 1 |
Willis, IM | 1 |
Soda, K | 1 |
Kano, Y | 1 |
Chiba, F | 1 |
Jamdar, SC | 1 |
Cao, WF | 1 |
Samaniego, E | 1 |
Sjöholm , A | 1 |
Arkhammar, P | 1 |
Berggren, PO | 1 |
Andersson, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effect of an Immediate-postpartum Support by IBCLC to Women With Obesity, on Breastfeeding Performance: A Randomized Trial.[NCT02756169] | 261 participants (Actual) | Interventional | 2016-07-14 | Completed | |||
TArgeting Type 1 Diabetes Using POLyamines (TADPOL): A Randomized, Double-Masked, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Difluoromethylornithine (DFMO) to Preserve Insulin Production in Type 1 Diabetes[NCT05594563] | Phase 2 | 70 participants (Anticipated) | Interventional | 2023-03-14 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
15 other studies available for spermidine and Obesity
Article | Year |
---|---|
Elevation of Serum Spermidine in Obese Patients: Results from a Cross-Sectional and Follow-Up Study.
Topics: Body Mass Index; Cross-Sectional Studies; Follow-Up Studies; Humans; Obesity; Overweight; Risk Facto | 2022 |
Spermine Suppresses Adipocyte Differentiation and Exerts Anti-Obesity Effects In Vitro and In Vivo.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Anti-Obesity Agents; Cell Differentiation; Lipids; Mice; Obesity; | 2022 |
Gender-Related Differences on Polyamine Metabolome in Liquid Biopsies by a Simple and Sensitive Two-Step Liquid-Liquid Extraction and LC-MS/MS.
Topics: Acetylation; Cadaverine; Chromatography, Liquid; Dansyl Compounds; Diamines; Female; gamma-Aminobuty | 2019 |
Spermidine supplementation and voluntary activity differentially affect obesity-related structural changes in the mouse lung.
Topics: Animal Feed; Animals; Body Weight; Diet, High-Fat; Dietary Supplements; Lung; Male; Mice; Mice, Inbr | 2020 |
Voluntary activity reverses spermidine-induced myocardial fibrosis and lipid accumulation in the obese male mouse.
Topics: Administration, Oral; Animals; Cardiomegaly; Diet, High-Fat; Fibrosis; Hypertrophy, Left Ventricular | 2021 |
Spermidine improves gut barrier integrity and gut microbiota function in diet-induced obese mice.
Topics: Animals; Autophagy; Body Weight; Caco-2 Cells; Cell Line, Tumor; Clostridiales; Dysbiosis; Endotoxem | 2020 |
Spermidine ameliorates high-fat diet-induced hepatic steatosis and adipose tissue inflammation in preexisting obese mice.
Topics: Adipose Tissue; Adipose Tissue, Brown; Animals; Anti-Obesity Agents; Diet, High-Fat; Fatty Liver; In | 2021 |
The Autophagy Inducer Spermidine Protects Against Metabolic Dysfunction During Overnutrition.
Topics: Adipose Tissue; Animals; Autophagy; Diet, High-Fat; Fibroblast Growth Factors; Liver; Mice; Mice, In | 2021 |
Oral Spermidine Targets Brown Fat and Skeletal Muscle to Mitigate Diet-Induced Obesity and Metabolic Disorders.
Topics: Adipose Tissue, Brown; Administration, Oral; Animals; Diet, High-Fat; Hypothalamus; Insulin Resistan | 2021 |
Spermidine ameliorates non-alcoholic fatty liver disease through regulating lipid metabolism via AMPK.
Topics: AMP-Activated Protein Kinases; Animals; Body Weight; Cells, Cultured; Diet, High-Fat; Fatty Acid Syn | 2018 |
Lower polyamine levels in breast milk of obese mothers compared to mothers with normal body weight.
Topics: Adult; Body Mass Index; Breast Feeding; Feeding Behavior; Female; Guidelines as Topic; Humans; Lacta | 2013 |
Loss of the RNA polymerase III repressor MAF1 confers obesity resistance.
Topics: Animals; Autophagy; Eating; Energy Metabolism; Lipid Metabolism; Longevity; Mice, Inbred C57BL; Mice | 2015 |
Food polyamine and cardiovascular disease--an epidemiological study.
Topics: Cardiovascular Diseases; Diet; Fruit; Global Health; Gross Domestic Product; Humans; Linear Models; | 2012 |
Relationship between adipose polyamine concentrations and triacylglycerol synthetic enzymes in lean and obese Zucker rats.
Topics: Acyltransferases; Adipose Tissue; Animals; Chromatography, High Pressure Liquid; Diacylglycerol O-Ac | 1996 |
Polyamines in pancreatic islets of obese-hyperglycemic (ob/ob) mice of different ages.
Topics: Age Factors; Animals; Cells, Cultured; DNA; Enzyme Inhibitors; Female; Insulin; Islets of Langerhans | 2001 |